Scientific Articles on Psychedelics: Difference between revisions
From DMT-Nexus Wiki
Jump to navigationJump to search
TheTraveler (talk | contribs) |
TheTraveler (talk | contribs) |
||
| Line 264: | Line 264: | ||
{{FileReference | {{FileReference | ||
|[[Image:Page_white_acrobat.png]] | |[[Image:Page_white_acrobat.png]] | ||
|[[Media: | |[[Media:bufo alvarius - a potent hallucinogen.pdf|Bufo alvarius - a potent hallucinogen]] | ||
| | | | ||
|0px | |0px | ||
| Line 270: | Line 270: | ||
{{FileReference | {{FileReference | ||
|[[Image:Page_white_acrobat.png]] | |[[Image:Page_white_acrobat.png]] | ||
|[[Media: | |[[Media:entheogens and education potential.pdf|Entheogens and education potential]] | ||
| | | | ||
|0px | |0px | ||
| Line 276: | Line 276: | ||
{{FileReference | {{FileReference | ||
|[[Image:Page_white_acrobat.png]] | |[[Image:Page_white_acrobat.png]] | ||
|[[Media: | |[[Media:hallucinogens and redemption.pdf|Hallucinogens and redemption]] | ||
| | | | ||
|0px | |0px | ||
| Line 282: | Line 282: | ||
{{FileReference | {{FileReference | ||
|[[Image:Page_white_acrobat.png]] | |[[Image:Page_white_acrobat.png]] | ||
|[[Media: | |[[Media:HPPD - flashbacks.pdf|HPPD - flashbacks]] | ||
| | | | ||
|0px | |0px | ||
| Line 288: | Line 288: | ||
{{FileReference | {{FileReference | ||
|[[Image:Page_white_acrobat.png]] | |[[Image:Page_white_acrobat.png]] | ||
|[[Media: | |[[Media:JPharmBioAn-41-3-872.pdf|JPharmBioAn-41-3-872]] | ||
| | | | ||
|0px | |0px | ||
| Line 294: | Line 294: | ||
{{FileReference | {{FileReference | ||
|[[Image:Page_white_acrobat.png]] | |[[Image:Page_white_acrobat.png]] | ||
|[[Media: | |[[Media:Mining_Recepterome_Review_JBC.pdf|Mining_Recepterome_Review_JBC]] | ||
| | | | ||
|0px | |0px | ||
}} | }} | ||
{{FileReference | {{FileReference | ||
|[[Image:Page_white_acrobat.png]] | |[[Image:Page_white_acrobat.png]] | ||
|[[Media: | |[[Media:natural hallucinogens growing in USA.pdf|Natural hallucinogens growing in USA]] | ||
| | | | ||
|0px | |0px | ||
| Line 314: | Line 306: | ||
{{FileReference | {{FileReference | ||
|[[Image:Page_white_acrobat.png]] | |[[Image:Page_white_acrobat.png]] | ||
|[[Media: | |[[Media:Nichols - Hallucinogens.pdf|Nichols - Hallucinogens]] | ||
| | | | ||
|0px | |0px | ||
| Line 320: | Line 312: | ||
{{FileReference | {{FileReference | ||
|[[Image:Page_white_acrobat.png]] | |[[Image:Page_white_acrobat.png]] | ||
|[[Media: | |[[Media:pharmañopo - Yopo pharmacology.pdf|Pharmañopo - Yopo pharmacology]] | ||
| | | | ||
|0px | |0px | ||
| Line 326: | Line 318: | ||
{{FileReference | {{FileReference | ||
|[[Image:Page_white_acrobat.png]] | |[[Image:Page_white_acrobat.png]] | ||
|[[Media: | |[[Media:pharmepena - epena pharmacology.pdf|Pharmepena - epena pharmacology]] | ||
| | | | ||
|0px | |0px | ||
| Line 332: | Line 324: | ||
{{FileReference | {{FileReference | ||
|[[Image:Page_white_acrobat.png]] | |[[Image:Page_white_acrobat.png]] | ||
|[[Media: | |[[Media:Proposed Mechanism for Dreams and Sleep.pdf|Proposed Mechanism for Dreams and Sleep]] | ||
| | | | ||
|0px | |0px | ||
| Line 338: | Line 330: | ||
{{FileReference | {{FileReference | ||
|[[Image:Page_white_acrobat.png]] | |[[Image:Page_white_acrobat.png]] | ||
|[[Media: | |[[Media:psychedelic adverse effects.pdf|Psychedelic adverse effects]] | ||
| | | | ||
|0px | |0px | ||
}} | }} | ||
{{FileReference | {{FileReference | ||
|[[Image:Page_white_acrobat.png]] | |[[Image:Page_white_acrobat.png]] | ||
|[[Media: | |[[Media:Psychointegrators multidisciplinary approach.pdf|Psychointegrators multidisciplinary approach]] | ||
| | | | ||
|0px | |0px | ||
| Line 360: | Line 342: | ||
{{FileReference | {{FileReference | ||
|[[Image:Page_white_acrobat.png]] | |[[Image:Page_white_acrobat.png]] | ||
|[[Media: | |[[Media:Psychopharmacology of hallucinogens.pdf|Psychopharmacology of hallucinogens]] | ||
| | | | ||
|0px | |0px | ||
| Line 366: | Line 348: | ||
{{FileReference | {{FileReference | ||
|[[Image:Page_white_acrobat.png]] | |[[Image:Page_white_acrobat.png]] | ||
|[[Media: | |[[Media:psychosis and hallucinogens consciousness model.pdf|Psychosis and hallucinogens consciousness model]] | ||
| | | | ||
|0px | |0px | ||
| Line 372: | Line 354: | ||
{{FileReference | {{FileReference | ||
|[[Image:Page_white_acrobat.png]] | |[[Image:Page_white_acrobat.png]] | ||
|[[Media: | |[[Media:reducing drug problems with set and setting.pdf|Reducing drug problems with set and setting]] | ||
| | | | ||
|0px | |0px | ||
| Line 378: | Line 360: | ||
{{FileReference | {{FileReference | ||
|[[Image:Page_white_acrobat.png]] | |[[Image:Page_white_acrobat.png]] | ||
|[[Media: | |[[Media:serotonin and hallucinogens.pdf|Serotonin and hallucinogens]] | ||
| | | | ||
|0px | |0px | ||
| Line 384: | Line 366: | ||
{{FileReference | {{FileReference | ||
|[[Image:Page_white_acrobat.png]] | |[[Image:Page_white_acrobat.png]] | ||
|[[Media: | |[[Media:study of Values of psychedelic users.pdf|Study of Values of psychedelic users]] | ||
| | | | ||
}} | }} | ||
[[Category:Supplementary Reference]] | [[Category:Supplementary Reference]] | ||
Revision as of 21:41, 16 February 2009
 |
Note: | This page is a work in progress -- its content throughout is not yet complete. |
Ayahuasca
|
Ayahuasca and SSRI Interactions | Callaway, J.T., C.S. Grob. (October-December 1998). Journal of Psychoactive Drugs. pp. 367-369. |
|
|
Ayahuasca Adolescents ritual use | Doering-Silveira et al. (June 2005). Journal of Psychoactive Drugs. Vol. 37 (2). pp. 141-144. |
|
|
ayahuasca first time psychological after effects | Hoffman et al. (Spring 2001). Multidisciplinary Association for Psychedelic Studies. pp. 25-30. |
|
|
Ayahuasca and human destiny | McKenna, Dennis J. (June 2005). Journal of Psychoactive Drugs. Vol. 37 (2) pp. 231-234. |
|
|
Another Ayahuasca EEG study | Riba et al. (2002). British Journal of Clinical Pharmacology. Vol. 53. Blackwell Science Ltd. pp. 617-628. |
|
|
Ayahuasca in adolescence psychiatric evaluation |
|
|
ayahuasca in cross cultural perspective |
|
|
Ayahuasca neuroimaging |
|
|
Bringing Ayahuasca to clinical laboratory |
|
|
Effects of ayahuasca on panic and anxiety.pdf |
|
|
Globalization of ayahuasca |
|
|
Human pharmacology of ayahuasca |
|
|
Pharmacokinetics of hoasca in healthy humans |
|
|
Risk assessment of ritual ayahuasca use |
|
|
Thesis - Ayahuascapharmacology part1 |
|
|
Thesis - ayahuascapharmacology part2 |
|
|
Various alkaloid profiles in aya decoction |
DMT
|
|
DMT and BCarbolines in human plasma after dose |
|
|
DMT endogenous anxiolytic role |
|
|
DMT in psychiatric patients |
|
|
DMT psychopharmacology |
|
|
Excretion of DMT in Psychiatric Patients |
Ibogaine
|
|
Fatalities after ibogaine use |
|
|
Ibogaine and cocaine abuse |
|
|
Ibogaine and facilitation of memory retrieval |
|
|
Ibogaine mechanisms of anti addiction |
|
|
Ibogaine safety and efficacy |
LSD
|
|
Long term effects of LSD |
|
|
Therapy with LSD |
Peyote
|
|
A Study on mescaline in human subjects |
|
|
Peyote long term psychological cognitive effects |
|
|
Prehistoric peyote use |
Psilocybin
|
|
Cluster headache lsd psilocybin |
|
|
Effects of psilocybin on humans |
|
|
Effects of psilocybin on perception of time |
|
|
Psilocybin and mystical experiences |
|
|
Psilocybin and OCD |
|
|
Psilocybin investigator brochure |
|
|
Psilocybin, attention and working memory |
|
|
Psychedelic mushrooms in buddhist tradition |
Salvia Divinorum
|
|
Salvia divinorum pattern of use |
|
|
Salv_A_PNAS |
Other
|
|
Bufo alvarius - a potent hallucinogen |
|
|
Entheogens and education potential |
|
|
Hallucinogens and redemption |
|
|
HPPD - flashbacks |
|
|
JPharmBioAn-41-3-872 |
|
|
Mining_Recepterome_Review_JBC |
|
|
Natural hallucinogens growing in USA |
|
|
Nichols - Hallucinogens |
|
|
Pharmañopo - Yopo pharmacology |
|
|
Pharmepena - epena pharmacology |
|
|
Proposed Mechanism for Dreams and Sleep |
|
|
Psychedelic adverse effects |
|
|
Psychointegrators multidisciplinary approach |
|
|
Psychopharmacology of hallucinogens |
|
|
Psychosis and hallucinogens consciousness model |
|
|
Reducing drug problems with set and setting |
|
|
Serotonin and hallucinogens |
|
|
Study of Values of psychedelic users |
